Skip to main content
MTVA
NASDAQ Life Sciences

MetaVia's DA-1726 Matches Retatrutide Weight Loss With Less Appetite Suppression in Preclinical Study

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1.27
Mkt Cap
$8.565M
52W Low
$0.966
52W High
$13.42
52W Position info
31% above low
Off High info
91% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

MTVA sits 31% above its 52-week low of $0.966.

Summary

MetaVia presented preclinical data showing DA-1726 matched retatrutide's weight loss in obese mice while suppressing appetite less and lowering glucose and lipids more, supporting a differentiated mechanism. The Phase 2 MetALD/ALD study is not targeted to begin until the second half of 2027.


Key Events · Product Development and Regulatory · MTVA

  • DA-1726 Matches Retatrutide in Mice

    In diet-induced obese mice, DA-1726 cut body weight 34.2% and 41.7% at low and high doses versus 33.7% and 43.6% for retatrutide, after adjustment relative to controls.

  • Less Appetite Suppression, Same Weight Loss

    DA-1726 reduced food intake by only 19.6% and 31.2% versus 36.7% and 41.4% for retatrutide, suggesting a larger share of weight loss comes from glucagon-driven energy expenditure.

  • Better Glucose and Lipid Numbers

    Plasma glucose fell 43.0% and 39.2% versus 21.5% and 32.5% for retatrutide; LDL cholesterol dropped 89.9% and 88.4% versus 82.8% and 88.1%.

  • Liver FGF21 Pathway Engaged

    Hepatic Fgf21 gene expression rose significantly (p<0.05), with liver FGF21 protein and circulating FGF21 up (p<0.001) at the higher dose — the mechanism the company ties to liver benefit.


Analysis · MTVA · Life Sciences

MetaVia now has a direct preclinical comparison against retatrutide, the triple agonist widely viewed as the efficacy benchmark in next-generation obesity drugs. DA-1726 delivered essentially the same weight loss (41.7% vs 43.6% at the high dose) while cutting food intake far less (31.2% vs 41.4%), which supports the company's thesis that glucagon-driven energy expenditure, not just appetite suppression, is doing the work. Stronger glucose and lipid lowering, plus a statistically significant rise in liver Fgf21, round out a differentiated story for a liver-focused metabolic asset. The caveat: this is mouse data presented at a conference, not human results, and the next real value inflection — a Phase 2 MetALD/ALD study — is not targeted to start until the second half of 2027, a long gap for a company with a going-concern warning and cash guided only into 1Q 2027.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MTVA was trading at $1.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.6M. The 52-week trading range was $0.97 to $13.42. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MTVA - Latest Insights

MTVA
Nov 13, 2026, 8:36 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.40
Real-time Price: $1.27 info
Change: -$0.130 (-9%) info
Market Cap: $8.565M info
MTVA
Nov 13, 2026, 8:35 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.40
Real-time Price: $1.27 info
Change: -$0.130 (-9%) info
Market Cap: $8.565M info
MTVA
Nov 13, 2026, 8:31 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.40
Real-time Price: $1.27 info
Change: -$0.130 (-9%) info
Market Cap: $8.565M info
MTVA
Nov 12, 2026, 8:41 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.51
Real-time Price: $1.27 info
Change: -$0.240 (-16%) info
Market Cap: $8.565M info
MTVA
Nov 05, 2026, 9:15 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.32
Real-time Price: $1.27 info
Change: -$0.0493 (-4%) info
Market Cap: $8.565M info